Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
LEIDEN, the Netherlands, Feb. 07, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis Type 10 (LCA10), today announced that Daniel de Boer, Chief Executive Officer and Smital Shah, Chief Financial Officer, will take part in an analyst led fireside chat during the LEERINK Partners Global Healthcare Conference on Wednesday, February 15, 2017 at 3:00pm ET. The conference is being held at the Lotte New York Palace in New York, NY, USA.
The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcast will be available for 30 days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Contact:
Sariette Witte
Investor Relations
T: +1 213 261 8891
[email protected]
